The former Woodford Patient Capital trust has benefited from the legacy invest in Oxford Nanopore, which contributed 94% of the Q3 NAV increase of 15.9%, according to Investec. The biotech firm set an offer price of 425 pence per share, which would have given the firm a total market capitalisation of approximately £3.4bn. However, the stock opened considerably higher at 545 pence per share before rising as high as 622 pence per share, up 47% on its initial offer price. However, away from the success of the IPO the trust is struggling with the portfolio it inherited from Neil Woodford....